Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)

SHE:002755 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,557	1,411	1,047	772.71	1,166	1,369
Trading Asset Securities	815.15	683.28	713.83	839.08	522.39	100
Cash & Short-Term Investments	2,372	2,095	1,761	1,612	1,688	1,469
Cash Growth	21.55%	18.96%	9.25%	-4.51%	14.90%	14.14%
Accounts Receivable	299.86	231.83	181.24	323.03	581.86	968.27
Other Receivables	11.51	13.02	49.88	25.21	16.29	24.79
Receivables	311.37	244.85	231.12	348.23	598.15	993.06
Inventory	150.62	196.99	167.49	141.53	141.84	168.74
Other Current Assets	29.15	31.59	27	36.56	59.14	16.01
Total Current Assets	2,863	2,568	2,186	2,138	2,487	2,647
Property, Plant & Equipment	439.66	474.03	478.4	547.14	658.33	706.66
Long-Term Investments	118.64	118.72	118.21	107.57	105.18	77.36
Other Intangible Assets	561.08	146.34	98.34	95.77	97.69	84.91
Long-Term Deferred Tax Assets	25.24	24.62	25.73	25.85	28.69	26.9
Long-Term Deferred Charges	361.22	676.78	563.46	453.7	342.02	257.47
Other Long-Term Assets	37.02	38.97	53.26	46.22	5.75	7.89
Total Assets	4,406	4,048	3,524	3,414	3,725	3,808
Accounts Payable	38.47	59.98	38.29	39.08	65.72	95.29
Accrued Expenses	27.62	40.84	43.6	119.56	133.48	299.13
Short-Term Debt	47	62	114.02	45.03	-	20.01
Current Portion of Leases	3.09	4.06	3.03	3.45	2.61	-
Current Income Taxes Payable	1.64	2.05	3.59	2.13	7.54	13.14
Current Unearned Revenue	237.4	108.51	15.88	11.68	15.26	31.18
Other Current Liabilities	758.94	543.53	213.14	102.81	177.11	231.23
Total Current Liabilities	1,114	820.96	431.55	323.74	401.71	689.99
Long-Term Leases	5.22	6.62	6.75	8.92	11.52	-
Long-Term Unearned Revenue	61.52	60.66	64.72	55.81	68.93	69.41
Long-Term Deferred Tax Liabilities	17.18	17.15	10.18	12.56	15.08	15.49
Total Liabilities	1,198	905.39	513.2	401.03	497.24	774.89
Common Stock	928.16	928.16	928.16	928.16	928.16	928.16
Additional Paid-In Capital	164.17	136.94	136.94	50.73	0.94	1.49
Retained Earnings	2,037	1,989	1,828	1,977	2,295	2,101
Comprehensive Income & Other	9.06	8.95	6.58	7.25	-5.9	-3.7
Total Common Equity	3,139	3,063	2,900	2,963	3,219	3,027
Minority Interest	69.48	79.59	110.7	50.37	8.82	6.06
Shareholders' Equity	3,208	3,142	3,011	3,013	3,228	3,033
Total Liabilities & Equity	4,406	4,048	3,524	3,414	3,725	3,808
Total Debt	55.31	72.67	123.8	57.41	14.13	20.01
Net Cash (Debt)	2,317	2,022	1,637	1,554	1,674	1,449
Net Cash Growth	23.89%	23.52%	5.32%	-7.14%	15.51%	12.58%
Net Cash Per Share	2.46	2.14	1.76	1.65	1.81	1.57
Filing Date Shares Outstanding	928.16	928.16	928.16	928.16	928.16	928.16
Total Common Shares Outstanding	928.16	928.16	928.16	928.16	928.16	928.16
Working Capital	1,749	1,747	1,755	1,814	2,085	1,957
Book Value Per Share	3.38	3.30	3.12	3.19	3.47	3.26
Tangible Book Value	2,578	2,916	2,802	2,867	3,121	2,942
Tangible Book Value Per Share	2.78	3.14	3.02	3.09	3.36	3.17
Buildings	385.91	385.96	375.5	371.29	437.94	436.85
Machinery	803.98	804.36	744.21	767.2	776.51	764.36
Construction In Progress	24.51	23.51	36.07	29.8	19.71	15.72

Source: S&P Global Market Intelligence. Standard template. Financial Sources.